Literature DB >> 32956767

Targeting tumor-associated macrophages for cancer immunotherapy.

Yongheng Shu1, Ping Cheng2.   

Abstract

Macrophages are important effector cells of the innate immune system and are also major components of the tumor microenvironment (TME). Macrophages that are abundant in the TME are called tumor-associated macrophages (TAMs). As TAMs promote strong tumor angiogenesis and support tumor cell survival, they are closely related to tumor growth. Several studies have demonstrated that reducing the density or effects of TAMs can inhibit the growth of tumors, making them targets for cancer immunotherapy, which has become a research hot spot. Several clinical and preclinical trials have studied drugs that inhibit the effects of and reduce the population of phagocytes that target TAMs achieve cancer immunotherapy. In this paper, we summarize the various methods of targeting TAMs for tumor immunotherapy, focusing on TAM mechanisms, sources, and polarization.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immunotherapy; Tumor; Tumor-associated macrophages (TAMs)

Mesh:

Substances:

Year:  2020        PMID: 32956767     DOI: 10.1016/j.bbcan.2020.188434

Source DB:  PubMed          Journal:  Biochim Biophys Acta Rev Cancer        ISSN: 0304-419X            Impact factor:   10.680


  23 in total

Review 1.  Helicobacter pylori promotes gastric cancer progression through the tumor microenvironment.

Authors:  Linqi Zhu; Yue Huang; Hong Li; Shihe Shao
Journal:  Appl Microbiol Biotechnol       Date:  2022-06-20       Impact factor: 4.813

Review 2.  CDC7 as a novel biomarker and druggable target in cancer.

Authors:  Runze Liu; Yong Huang
Journal:  Clin Transl Oncol       Date:  2022-06-03       Impact factor: 3.340

3.  Tumor-Associated Macrophages Correlate With Prognosis in Medulloblastoma.

Authors:  Jin Zhang; Xia Yuan; Yuan Wang; Jingjing Liu; Zhigang Li; Shuting Li; Yan Liu; Xiaojun Gong; Yanling Sun; Wanshui Wu; Liming Sun; Shuxu Du; Tianyou Wang
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

Review 4.  Noncoding RNA-mediated macrophage and cancer cell crosstalk in hepatocellular carcinoma.

Authors:  Zhixia Zhou; Zhan Wang; Jie Gao; Zhijuan Lin; Yin Wang; Peipei Shan; Mengkun Li; Tingting Zhou; Peifeng Li
Journal:  Mol Ther Oncolytics       Date:  2022-03-16       Impact factor: 6.311

Review 5.  Engineering Macrophages via Nanotechnology and Genetic Manipulation for Cancer Therapy.

Authors:  Xiaoling Ding; Xinchen Sun; Huihui Cai; Lei Wu; Ying Liu; Yu Zhao; Dingjingyu Zhou; Guiping Yu; Xiaorong Zhou
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

Review 6.  The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment.

Authors:  Yingli Guo; Yajuan Xie; Yao Luo
Journal:  Front Immunol       Date:  2022-02-09       Impact factor: 7.561

Review 7.  Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment.

Authors:  Pedram Moeini; Paulina Niedźwiedzka-Rystwej
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

8.  Self-assembled tetrahedral framework nucleic acid mediates tumor-associated macrophage reprogramming and restores antitumor immunity.

Authors:  Husun Qian; Ting Zhou; Yixin Fu; Minkang Guo; Wu Yang; Dian Zhang; Wenli Fang; Mengli Yao; He Shi; Chengsen Chai; Wei Cheng; Shijia Ding; Tingmei Chen
Journal:  Mol Ther Nucleic Acids       Date:  2022-01-03       Impact factor: 8.886

9.  m6A-related lncRNAs predict prognosis and indicate immune microenvironment in acute myeloid leukemia.

Authors:  Fangmin Zhong; Fangyi Yao; Ying Cheng; Jing Liu; Nan Zhang; Shuqi Li; Meiyong Li; Bo Huang; Xiaozhong Wang
Journal:  Sci Rep       Date:  2022-02-02       Impact factor: 4.379

10.  Prognostic Significance of Tumor-Associated Macrophages in Chondroblastoma and Their Association with Response to Adjuvant Radiotherapy.

Authors:  Yi-Guo Yan; Ming-Xiang Zou; Bo-Wen Zheng; Min-Liang Yang; Wei Huang; Bo-Yv Zheng; Tao-Lan Zhang; Jing Li; Guo-Hua Lv
Journal:  J Inflamm Res       Date:  2021-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.